Trial reportBMC anesthesiology2025
90% minimum effective concentration of ropivacaine for ultrasound-guided supra-inguinal fascia Iliaca compartment block for postoperative analgesia following total hip arthroplasty: a dose-finding study.
Trial report in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe ultrasound-guided supra-inguinal fascia iliaca compartment block (S-FICB) is a widely utilized regional anesthesia technique for postoperative pain management following total hip arthroplasty. Current evidence suggests that effective analgesia with S-FICB necessitates the administration of relatively high volumes of local anesthetic, which may consequently elevate the risk of local anesthetic toxicity and contribute to postoperative lower limb motor block.
methodsFifty-four patients with total hip arthroplasty were enrolled. Ultrasound-guided S-FICB was applied, the volume of the local anesthetic ropivacaine was set to 30 ml. Using the biased-coin design (BCD) sequential allocation method. The initial concentration of 30 ml ropivacaine was 0.25% and the interval concentration at 0.025%. Positive postoperative analgesia following S-FICB was defined by the simultaneous fulfillment of the following criteria: (1) The S-FICB block was successful. (2) The Visual Analogue Scale (VAS) scores maintained < 4 at 6, 12, 24 h postoperatively. (3) The effective compression times of Patient-Controlled Intravenous Analgesia (PCIA) < 5 within 24 h postoperatively. Failure to meet any one of these criteria was classified as negative postoperative analgesia. If the previous patient had a positive postoperative analgesia, the next patient was randomized to a lower concentration (defined as the previous concentration with a decrement of 0.025%), with an 11% probability (b = 0.11), or it would be administered the same concentration, with an 89% probability (1-b = 0.89). If a negative postoperative analgesia occurred, the next patient received a higher concentration (defined as the previous concentration with a increment of 0.025%). The study was terminated when 45 positive postoperative analgesia were achieved.
resultsForty-five patients (83%) were positive postoperative analgesia. The 90% minimum effective concentration (MEC90) of 30 ml ropivacaine for ultrasound guided S-FICB for postoperative analgesia following total hip arthroplasty was 0.286 (95% CI, 0.242 ~ 0.338) and the 95% minimum effective concentration (MEC95) was 0.314 (95% CI, 0.241 ~ 0.410).
conclusionThe MEC90 and MEC95 of 30 ml ropivacaine for ultrasound guided S-FICB for postoperative analgesia were 0.286% and 0.314%, respectively.
trial registrationThe trial was registered at the Chinese Clinical Trial Registry (registration number: ChiCTR2400092413, registration date: 2024 November 15).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.